A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
Public ClinicalTrials.gov record NCT02431702. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to compare effectiveness of paliperidone palmitate (PP: paliperidone palmitate once-monthly and 3-month injections) versus oral antipsychotic (OAP \[that is oral paliperidone extended release {ER}, oral risperidone, or another OAP\]) in delaying time to treatment failure. The study will also evaluate changes in cognition, functioning, brain intracortical myelin (ICM) volume following treatment with PP compared with OAP in participants with recent-onset schizophrenia or schizophreniform disorder.
Study identification
- NCT ID
- NCT02431702
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 337 participants
Conditions and interventions
Conditions
Interventions
- Aripiprazole Drug
- Haloperidol Drug
- Olanzapine Drug
- Oral Paliperidone ER Drug
- Perphenazine Drug
- Quetiapine Drug
- Oral Risperidone Drug
- Paliperidone Palmitate Injection (PP1M) Drug
- Paliperidone Palmitate Injection (PP3M) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 35 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 8, 2015 (Actual)
- Primary completion
- Nov 12, 2019 (Actual)
- Completion
- Nov 12, 2019 (Actual)
- Last update posted
- Apr 29, 2025
2015 – 2019
United States locations
- U.S. sites
- 34
- U.S. states
- 17
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Garden Grove | California | — | — |
| Not listed | Lemon Grove | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | San Rafael | California | — | — |
| Not listed | Stanford | California | — | — |
| Not listed | Lauderdale Lakes | Florida | — | — |
| Not listed | Leesburg | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | West Palm Beach | Florida | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Granite City | Illinois | — | — |
| Not listed | Hoffman Estates | Illinois | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Worcester | Massachusetts | — | — |
| Not listed | East Lansing | Michigan | — | — |
| Not listed | Grand Rapids | Michigan | — | — |
| Not listed | Muskegon | Michigan | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Cedarhurst | New York | — | — |
| Not listed | Rochester | New York | — | — |
| Not listed | Staten Island | New York | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Columbus | Ohio | — | — |
| Not listed | Eugene | Oregon | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Bothell | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02431702, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 29, 2025 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02431702 live on ClinicalTrials.gov.